Conditions: Prostate Cancer
Keywords: Fermented Soy
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 19
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy of Fermented Soy vs. placebo in 72 adults with localized prostate cancer prior to radical prostatectomy.

Detailed description:
This is a parallel group, double-blind, randomized clinical trial with two arms. The primary aim is to assess the efficacy of Fermented Soy vs. placebo in 72 adults with prostate cancer. This study has 1 primary aim and 3 (1a thru 1c) sub aims. Aim 1 is to assess the effect of Fermented Soy (QC) on PSA (prostate specific antigen) In parallel, in Aims 1a-1c will assess tumor-specific effects of QC:

Aim 1a: Identifying the anti-tumor effects of QC. This will be done by culturing multiple human cancer cell lines with QC at a range of concentrations, followed by readouts at different time points, of tumor cell apoptosis, proliferation, and senescence.

Aim 1b: Identify a hierarchy of tumors that are responsive to QC. From the data in aim one an attempt will be made to identify a hierarchy of anti-tumor effects.

Aim 1c: Investigate the signaling pathways in tumor cells that are modified by QC. To do this, full genomic profiling will be conducted for breast and prostate tumor cell lines, and will be done in conjunction with analysis of the relevant signaling pathways, and will include P53 and P21 activation pathways.

Arms:
arm 1: Daily Fermented Soy (two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline. arm 2: Daily (matched dose) taken between the time of enrollment and radical prostatectomy (RP). Clinical assessment of both groups will take place 1) at baseline, and 2) just prior to RP, estimated at between 4 and 10 weeks from baseline/enrollment. Length of time in the study will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies will be scheduled to occur between 4-10 weeks post-baseline.

Interventions: intervention 1: Fermented Soy intervention 2: Placebo
Intervention descriptions: intervention 1: Two 12.5g packets/day) (\~1 ounce/day) taken between the time of enrollment and radical prostatectomy (RP). Time can be between 4 and 10 weeks. intervention 2: A placebo compliment to the active intervention with identical packaging and labeling will be used.

Protocol document:
Prot_000.pdf: 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Protocol Number: 2000020868
Principal Investigator: Michael S. Leapman, MD
IND Sponsor: Michael S. Leapman, MD
Funded by: BESO Biological Research Center, Inc.
Version Number:  v.3.1
01 November 2019
Amendment History 
Version 
Date
v.1.0
29 March 2018
v.2.0
26 September 2018
v.3.0
18 September 2018
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
 
Table of Contents
STATEMENT OF COMPLIANCE.......................................................................................................................................1
1
PROTOCOL SUMMARY......................................................................................................................................1
1.1
Synopsis..................................................................................................................................................1
1.2
Schema...................................................................................................................................................3
1.3
Schedule of Activities (SoA)....................................................................................................................4
2
INTRODUCTION.................................................................................................................................................4
2.1
Study Rationale ......................................................................................................................................4
2.2
Background ............................................................................................................................................4
2.3
Risk/Benefit Assessment........................................................................................................................6
2.3.1
Known Potential Risks ........................................................................................................7
2.3.2
Known Potential Benefits ...................................................................................................7
2.3.3
Assessment of Potential Risks and Benefits .......................................................................7
3
OBJECTIVES AND ENDPOINTS ...........................................................................................................................7
4
STUDY DESIGN ..................................................................................................................................................9
4.1
Overall Design ........................................................................................................................................9
4.2
Scientific Rationale for Study Design....................................................................................................10
4.3
Justification for Dose............................................................................................................................10
4.4
End of Study Definition ........................................................................................................................10
5
STUDY POPULATION .......................................................................................................................................10
5.1
Inclusion Criteria ..................................................................................................................................10
5.2
Exclusion Criteria..................................................................................................................................10
5.3
Lifestyle Considerations .......................................................................................................................11
5.4
Screen Failures .....................................................................................................................................11
5.5
Strategies for Recruitment and Retention ...........................................................................................11
6
STUDY INTERVENTION ....................................................................................................................................12
6.1
Study Intervention(s) Administration...................................................................................................12
6.1.1
Study Intervention Description.........................................................................................12
6.1.2
Dosing and Administration ...............................................................................................12
6.2
Preparation/Handling/Storage/Accountability ....................................................................................13
6.2.1
Acquisition and accountability..........................................................................................13
6.2.2
Formulation, Appearance, Packaging, and Labeling.........................................................13
6.2.3
Product Storage and Stability ...........................................................................................14
6.2.4
Preparation.......................................................................................................................14
6.3
Measures to Minimize Bias: Randomization and Blinding ...................................................................14
6.4
Study Intervention Compliance............................................................................................................15
6.5
Concomitant Therapy...........................................................................................................................16
7
STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT DISCONTINUATION/WITHDRAWAL .............16
7.1
Discontinuation of Study Intervention.................................................................................................16
7.2
Participant Discontinuation/Withdrawal from the Study ....................................................................16
7.3
Lost to Follow-Up .................................................................................................................................17
8
STUDY ASSESSMENTS AND PROCEDURES.......................................................................................................17
8.1
Efficacy Assessments............................................................................................................................17
8.2
Safety and Other Assessments.............................................................................................................19
8.3
Adverse Events and Serious Adverse Events........................................................................................20
8.3.1
Definition of Adverse Events (AE).....................................................................................20
8.3.2
Definition of Serious Adverse Events (SAE) ......................................................................20
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
 
8.3.3
Classification of an Adverse Event....................................................................................20
8.3.4
Time Period and Frequency for Event Assessment and Follow-Up..................................21
8.3.5
Adverse Event Reporting ..................................................................................................22
8.3.6
Serious Adverse Event Reporting .....................................................................................22
8.3.7
Reporting Events to Participants ......................................................................................22
8.4
Unanticipated Problems.......................................................................................................................23
8.4.1
Definition of Unanticipated Problems (UP) ......................................................................23
8.4.2
Unanticipated Problem Reporting....................................................................................23
8.4.3
Reporting Unanticipated Problems to Participants..........................................................24
9
STATISTICAL CONSIDERATIONS.......................................................................................................................24
9.1
Statistical Hypotheses ..........................................................................................................................24
9.2
Sample Size Determination ..................................................................................................................25
9.3
Populations for Analyses......................................................................................................................25
9.4
Statistical Analyses...............................................................................................................................25
9.4.1
General Approach.............................................................................................................25
9.4.2
Analysis of the Primary Efficacy Endpoint(s) ....................................................................26
9.4.3
Analysis of the Secondary Endpoint(s) .............................................................................26
9.4.4
Safety Analyses.................................................................................................................27
9.4.5
Baseline Descriptive Statistics ..........................................................................................27
9.4.6
Planned Interim Analyses .................................................................................................28
9.4.7
Sub-Group Analyses..........................................................................................................28
9.4.8
Tabulation of Individual participant Data.........................................................................28
9.4.9
Exploratory Analyses ........................................................................................................28
10
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS ......................................................29
10.1
Regulatory, Ethical, and Study Oversight Considerations ....................................................................29
10.1.1
Informed Consent Process................................................................................................29
10.1.2
Study Discontinuation and Closure...................................................................................30
10.1.3
Confidentiality and Privacy...............................................................................................30
10.1.4
Future Use of Stored Specimens and Data.......................................................................31
10.1.5
Key Roles and Study Governance .....................................................................................32
10.1.6
Safety Oversight................................................................................................................32
10.1.7
Clinical Monitoring ...........................................................................................................33
10.1.8
Quality Assurance and Quality Control.............................................................................33
10.1.9
Data Handling and Record Keeping ..................................................................................33
10.1.10
Protocol Deviations ..........................................................................................................34
10.1.11
Publication and Data Sharing Policy .................................................................................35
10.1.12
Conflict of Interest Policy..................................................................................................35
10.2
Additional Considerations....................................................................................................................35
10.3
Abbreviations .......................................................................................................................................35
10.4
Protocol Amendment History..................................................................Error! Bookmark not defined.
11
REFERENCES....................................................................................................................................................37
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
1
STATEMENT OF COMPLIANCE
The trial will be conducted in accordance with International Conference on Harmonisation Good Clinical 
Practice (ICH GCP), applicable United States (US) Code of Federal Regulations (45 CFR 46), the Yale 
University Human Research Protection Program (HRPP) and the Yale Institutional Review Board.  The 
Principal Investigator will assure that no deviation from, or changes to the protocol will take place 
without prior agreement from the Investigational New Drug (IND) funding agency and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate 
hazard(s) to the trial participants. All personnel involved in the conduct of this study have completed 
Human Subjects Protection and FDA GCP Training.
The protocol, informed consent form, recruitment materials, and all participant materials have been 
submitted to the IRB for review and approval.  Approval of both the protocol and the consent form will 
be obtained before any participant is enrolled.  Any amendment to the protocol will require review and 
approval by the IRB before the changes are implemented to the study.  All changes to the consent form 
will be IRB-approved; a determination will be made regarding whether a new consent needs to be 
obtained from participants who provided consent, using a previously approved consent form.
1
PROTOCOL SUMMARY
1.1
SYNOPSIS 
Title:
Nutrition and Prostate Cancer: Assessing the Clinical Response of 
Prostate Cancer to Fermented Soy 
Study Description:
This is a parallel group, double blind, randomized, controlled trial to assess 
the efficacy of a fermented soy product (Q-CAN® Plus or “QC”) vs. placebo, 
in 72 adults with localized prostate cancer prior to prostatectomy.  We 
propose a line of inquiry to assess the effects of QC in humans, assessing 
immunological and clinical parameters. 
Objectives:
Primary Objective:  To assess the efficacy of QC vs. placebo in 72 adults 
with localized prostate cancer prior to radical prostatectomy. 
Secondary Objectives: To assess the efficacy of QC on disease progression, 
prostate cancer biomarkers, and quality of life.
Endpoints:
Primary Endpoint:  Serum PSA (prostate specific antigen)
Secondary Endpoints: 
1. Volume of prostate gland  
2. Volume of biopsy-proven, index prostate cancer (PCa) lesion 
3. Gleason score compared to preoperative biopsies 
4. PCa tissue telomeric DNA length 
5. Cancer of the Prostate Risk Assessment (CAPRA-S) post-surgical
     score
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
2
6. Cell cycle progression score assessment of PCa mRNA
7. Specific marker changes on PCa tissue microarrays using
   automated quantitative analysis (AQUA)
8. Functional Assessment of Cancer Therapy – Prostate (FACT-P 4©)
Study Population:
The study population (N=72) will consist of men with histologically verified 
prostate cancer (at any stage) aged 18 years and older, scheduled for 
radical prostatectomy within 4-10 weeks at Yale New Haven Hospital in 
New Haven, CT, or Lawrence+Memorial Hospital in New London, CT, or 
South County Hospital in Wakefield, RI.  
Phase:
Phase 3 trial
Description of 
Sites/Facilities Enrolling 
Participants:
This is a multi-site study being conducted at Yale University School of 
Medicine, New Haven, CT, Lawrence+Memorial Hospital in New London, 
CT, and South County Hospital in Wakefield, RI, USA.  The Yale New Haven 
Health System (YNHHS) is a non-profit healthcare system with corporate 
headquarters in New Haven, CT.  Yale New Haven Health operates five 
delivery networks, one of which is Lawrence+Memorial Hospital (LMH). 
South County Hospital (SCH) is an independent, non-profit acute care 
hospital serving southern Rhode Island. All study urologists/Co-
Investigators have appointments in Yale University School of Medicine.
Description of Study 
Intervention:
We will assess the efficacy of a fermented soy extract in a placebo-
controlled study of 72 adult males with localized prostate cancer.  Over 
the course of 4-10 weeks (between baseline and prostatectomy), subjects 
will consume two 12.5-gram packets of soy or matched dose placebo per 
day. 
Study Duration:
36 months
Participant Duration:
The time it will take for each individual participant to complete all 
participant visits will vary (4-10 weeks), depending on the surgery date of 
each individual’s prostatectomy.
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
3
1.2
SCHEMA
Flow diagram of Study Schema 
Prior to 
Enrollment
Visit 1
 
Visit 2
 
Weeks 
  2-10a
 
Visit 3
a Duration in the study varies (between 4-10 weeks), and is dependent upon each subject’s date for surgery. 
  Obtain informed consent. Screen potential participants by inclusion and exclusion 
criteria; obtain history, document.
Perform Baseline assessments.
Refer to Section 1.3, Schedule of Activities
Beginning 1 week after Visit 2: 
Weekly phone calls to participants to assess safety, adherence/dosing. 
Final Assessments
Refer to Section 1.3, Schedule of 
Activities
Arm 2: Control
N=36 
Arm 1: Intervention 
N=36 
Administer assigned IP.   
Randomize
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
4
1.3
SCHEDULE OF ACTIVITIES (SOA) 
Procedures
 Screening/Baseline
Day -7 to -1
Study Visit 1
Day 1 +/-3 days
Phone Assessment 1
Day 7 +/- 1 day
 Phone Assessment 2
Day 14 +/-1 day
Phone Assessment 3
Day 21 +/-1 day
 Phone Assessment 4
Day 28 +/-1 day
Phone Assessment 5
Day 35 +/-1 day
Phone Assessment 6 
Day 42 +/-1 day
Phone Assessment 7
Day 49 +/-1 day
Phone Assessment 8
Day 56 +/-1 day
Phone Assessment 9
Day 63 +/- 1 day
Phone Assessment 10
Day 70 +/-1 day
Final Study Visit 2
Day 77 +/- 1 day
Informed consent
X
Demographics
X
Medical history
X
Anthropometrics (height, weight)
X
Concomitant medication review
X
X
X
X
X
X
X
X
X
X
X
X
X
Soy consumption inventory
X
FACT-P QoL questionnaire
X
X
Serology †
X
X
Randomization/Enrollment
X
IP dispensed
X
X
IP consumed ††
X
X
X
X
X
X
X
X
X
X
X
X
Weekly telephone calls †† assessing 
adherence/IP accountability, safety
X
X
X
X
X
X
X
X
X
X
X
Adverse event review and evaluation
X
X
X
X
X
X
X
X
X
X
X
Other laboratory assessments †††
(Telomere assay, CCP, AQUA)
 
† Amylase, CBC with diff, CMP, CRP, estrogen, ESR, IGF-1, IGFBP-1, IGFBP-2, IGFBP-3, lipase, lipid panel, PHI (prostate  
           health index - includes PSA), testosterone (total, bioavailable and free), and TSH. 
          †† Duration in the study varies (between 4-10 weeks), and is dependent upon each subject’s date for surgery.
        ††† Biopsied prostate tissue (pre-enrollment) and the excised prostate are biobanked by pathology outside the clinical trial’s 
           schedule of activities, regardless of participation.  At Screening/Baseline, participants are consented for analysis of their 
           frozen prostate tissue (to conduct the telomere assay, CCP, and AQUA laboratory assessments) after the study 
          has concluded enrollment. 
        
2
INTRODUCTION
2.1
STUDY RATIONALE 
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men in the Western world. 
Prostate cancer is often localized and grows slowly, so men may live for many years with the disease. 
However, some forms of prostate cancer may behave more aggressively and is an important cause of 
morbidity and mortality. Given the protracted, yet potentially fatal, natural history of the disease, there 
is growing interest in low-toxicity interventions in the tertiary prevention of morbidity and mortality due 
to prostate cancer.1
2.2
BACKGROUND 
Soy Isoflavones and Prostate Cancer
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
5
Genistin is an isoflavone found in a number of dietary plants such as soy. Genistin is also converted to a 
more familiar genistein, thus, the biological activities including anti-atherosclerotic, estrogenic and 
anticancer effects are analogous.  
Genistin, genistein and other isoflavones have been identified as angiogenesis inhibitors, and found to 
inhibit the uncontrolled cell growth of cancer, most likely by inhibiting the activity of substances in the 
body that regulate cell division and cell survival (growth factors). Various studies have found that 
moderate doses of genistein have inhibitory effects on cancers of the prostate, cervix, brain, breast, and 
colon.2,3 
Studies on rodents have found genistein to be useful in the treatment of leukemia, and that it can be 
used in combination with certain other anti-leukemic drugs to improve their efficacy.4
A recent systematic review assessed the role of genistein in prostate cancer, where the effect of 
genistein supplementation was investigated in two studies. In men randomized to 30 mg genistein daily 
for three to six weeks prior to prostatectomy, differences in favor of the experimental, versus control, 
group were reported for percentage change in PSA (p = 0.051), cellular response (p = 0.033), and cell 
proliferation (p < 0.001). However, the trial was assessed as having high or unclear risk of bias on four of 
the seven criteria, and it was assessed to have low risk of bias for sequence generation and blinding of 
participants, as well as selective outcome reporting.5 Comparably, in a trial with relatively low risk of 
bias, in men undergoing watchful waiting, randomization to 60 mg genistein daily versus an isocaloric 
placebo for 12 weeks had no impact on mean change in PSA.1
Q-CAN® Plus and Fermented Soy
There is an emerging literature demonstrating bioactive effects of ZhenHua 851 (Q-CAN® Plus or “QC”), 
a fermented soy food in humans. Uncontrolled studies and case reports support benefits in cancer 
progression and changes in activation markers in humans’ immune cells including changes in expression 
of CD3, CD4, and CD8 markers, as well increased NK cell activity. These are generic changes in immune 
activation and are associated with increased anti-cancer activity. Case reports associate consumption of 
QC with reduced prostate specific antigen (PSA) velocity in men with prostate cancer. Fermented soy 
products are reported to have increased isoflavone concentration6 compared to standard soy foods, and 
may contain a rich mixture of probiotic species.
 
Yang et al. reported that 13-methyltetradecanoic acid (13-MTD), a possible active ingredient in QC, 
inhibited growth of various cancer cell lines through the induction of apoptosis without adverse effects.7 
Furthermore, Lin et al. found induction of mitochondrial-mediated apoptosis through regulation of the 
AKT and MAPK pathways.8 Most recently, Cai et al. reported that 13-MTD inhibits proliferation and 
induces apoptosis through the down-regulation of AKT phosphorylation followed by caspase activation.9
Identifying the anti-cancer profile of QC in human cancer cell lines
13-MTD has been demonstrated to induce apoptosis of a range of human cancer cell lines (HT-29-colon, 
MCF7-breast [estrogen sensitive], MDA-MB-231-breast [estrogen insensitive], LNCaP-prostate 
[androgen sensitive], DU 145-prostate [androgen insensitive], NCI-SNU-1-stomach, SNU-423-liver, NCI-
H1688-lung, BxPC3-pancreas) in a concentration range of 10-25µg/ml.7 The reductionist approach of 
testing a single metabolite in QC is helpful as it can provide mechanistic insight into the biological 
actions. It also has disadvantages, and primary among these is that beneficial effects of QC may be due 
to the combinations of effects of the QC metabolites, and such effects will be missed when only single 
metabolites such as 13-MTD are investigated. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
6
Preliminary Studies Conducted at the Yale School of Medicine
We have recently produced data showing that 13-MTD can reduce IL-6 production from activated 
macrophages. As IL-6 contributes to the development of cachexia, this may result in a beneficial clinical 
response in addition to any direct anti-tumor effects.
Our team recently completed a comprehensive independent analysis of QC.10 In order to validate the 
Certificate of Analysis, the soy test agent (QC) underwent quarantine and independent third party 
laboratory analysis (product characterization) for: total soy isoflavones and essential fatty acids, 
aflatoxins, authenticity (GMO status), microbial contamination, heavy metals, residual solvents and 
herbicides, pesticides and fungicides. Selected, individual methods are referenced in the results section 
under their corresponding tables. Q-CAN® Plus contained 290.12 mg of total soy isoflavones and 5.48 g 
of total fatty acids per 240 ml. Qualitative PCR assays for CaMV 35s promoter and MON89788 RR2 
soybean were negative, indicating that no soy genetically modified organisms were present. Aflatoxins 
were not detected. Enterobacteriaceae, E. coli, Salmonella (spp), S. aureus, Pseudomonas aeruginosa, 
mold and yeast were absent, demonstrating a sterile product. A profile of 300 herbicides, pesticides and 
fungicides was negative and none of the 52 chemical residual solvents tested above the limit of 
quantification. Lead, mercury, arsenic, and cadmium were all below the detectable limit (5-10 ppb). 
Among the isoflavones isolated in significant quantities were genistein and genestin. In this independent 
evaluation, the manufacturer’s Certificate of Analysis was validated.
We are currently assessing data from the consumption of QC in 10 lean and 10 obese, otherwise healthy 
adults (Yale HIC/IRB #1507016139). During the 14-week study, participants consumed 16oz of QC daily 
for 4 weeks (week 3 through week 7). The oral and fecal microbiome of each participant was assayed 
starting at baseline, from saliva and stool samples. Samples were collected once a week, for the first 7 
weeks of the study, then every other week for the remainder of the study.  This sampling regimen is 
intended to reveal any changes in the microbiome due to consumption of QC and the persistence of any 
changes for 7 weeks after cessation of QC. Blood was also collected at 8 time points throughout the 
study to assay activation of the inflammasome machinery in peripheral blood cells. Results from these 
microbiome and blood assays are being compared between the lean and obese groups. Other measures 
of the study included BMI and a 24-hour dietary recall.  The study closed to enrollment when targeted 
accrual was met in August 2017. We are performing ongoing correlative laboratory testing of specimens 
obtained in blood and stool.
Based on participant reports in the preliminary study, QC was both palatable and tolerable (only one 
participant withdrew), with no adverse effects besides some reports of mild gastrointestinal symptoms. 
Thus, the palatability and tolerability of the product dosing in the preliminary study (two 8-oz. 
bottles/day) serves, in part, as the basis for dosage in the proposed study. The product characterization 
(noted above) further justifies dosing for the proposed study, as the laboratory analysis demonstrated 
that this dose contains 141 mg of genistin and 26 mg of genistein per 8 oz. (240 ml) bottle. 
We propose a line of inquiry to assess the effects of QC fermented soy consumption in humans, 
assessing immunological and clinical parameters. 
2.3
RISK/BENEFIT ASSESSMENT  
 
2.3.1
KNOWN POTENTIAL RISKS 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
7
Immediate risks:  There is a risk of allergic reaction to any soy product, such as hives, itching, abdominal 
discomfort, aversion and anaphylaxis. Persons allergic or sensitive to soy are excluded from the study.  
Participants in this study will be asked to consume GRAS foods - a brown rice-based placebo or 
fermented soy. 
Preliminary testing indicated that Q-CAN® Plus oral liquid had no toxic effects, even when large doses 
were taken acutely. In our preliminary safety/tolerability study with healthy volunteers (N=20), some 
participants reported mild, short-lasting gastrointestinal symptoms with the daily intake of the 
fermented soy beverage: nausea (3), stomach pain (1), diarrhea (1), and bloating (4). 
There is a small risk that when blood is drawn, participants may experience pain at the venipuncture 
site, bruising, or fainting, and in rare instances infection. This is very unlikely to occur, as all 
phlebotomists where subject visits will occur are trained, certified, and experienced in standard 
phlebotomy procedures. 
Long-range risks:  As with any trial, there is potential risk of loss of confidentiality; however, every effort 
will be made to keep participant information confidential, including study team training in GCP and 
HIPAA Privacy and Security, and limiting access to any related health information to only the small 
number of individuals who require access to carry out their role in the study. 
2.3.2
KNOWN POTENTIAL BENEFITS 
Immediate potential benefits: We anticipate beneficial changes in prostate condition in association with 
fermented soy consumption.  
Long-range potential benefits: We hope that the results of the study will help researchers better 
understand the role of fermented soy in relation to its anti-tumor effects, signaling pathways in tumor 
cells, which will add to scientific knowledge in prostate cancer. 
2.3.3
ASSESSMENT OF POTENTIAL RISKS AND BENEFITS 
This is a minimal risk study; refer to Section 2.3.1, Known Potential Risks. 
3
OBJECTIVES AND ENDPOINTS
OBJECTIVES
ENDPOINTS
JUSTIFICATION FOR 
ENDPOINTS
Primary
To assess the efficacy of QC 
fermented soy vs. placebo in 72 
adults with localized prostate 
cancer (PCa) prior to radical 
prostatectomy.
The primary assessment will be a 
comparison between participants 
in the QC arm vs. the placebo arm, 
in mean serum PSA (prostate-
specific antigen) level changes, 
from baseline and time of 
admission for surgery. 
Fermented soy 
supplementation/soy isoflavones 
are known to decrease serum 
PSA, the levels of which are used 
to indicate prostate health. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
8
OBJECTIVES
ENDPOINTS
JUSTIFICATION FOR 
ENDPOINTS
Secondary
To assess the efficacy of QC on 
disease progression (1, 2, 3, 4, 
5), PCa biomarkers (6, 7), and 
quality of life (8). 
1. Volume of prostate gland 
2. Volume of biopsy-proven, index 
     PCa lesion 
3. Gleason score compared to
      preoperative biopsies 
4. PCa tissue telomeric DNA length 
5. Cancer of the Prostate Risk 
Assessment (CAPRA-S) score
6. Cell cycle progression score 
assessment of prostate cancer 
mRNA from PCa tissue
7. Specific marker changes on PCa 
tissue microarrays (TMAs) using 
AQUA - automated quantitative 
analysis
8. Functional Assessment of Cancer 
Therapy – Prostate (FACT-P v4©) 
1, 2, 3:  Pathological investigation 
of the removed prostate gland, 
to analyze any modulation of PCa 
grade (Gleason score) compared 
to preoperative biopsies, volume 
of gland and of biopsy-proven, 
index prostate cancer lesion, and 
extent (involvement of surgical 
margins and extraprostatic 
extension) of clinical and 
pathological tumor stage and 
degree of tumor focality.
4. Analysis of telomere length in 
research samples of human 
peripheral blood mononuclear 
cells reveals that telomere length 
decreases with increased 
replication of cells, reflecting the 
replicative history of those cells. 
5. Post surgical/post intervention 
CAPRA score for comparison with 
baseline 
6. Cell cycle progression score 
assessment of PCa mRNA (from 
PCa tissue before and after 
treatment and between 
treatment arms) is a novel RNA 
expression-based assay that 
directly measures tumor cell 
growth characteristics in order to 
stratify patients with localized 
PCa according to disease 
aggressiveness. 
7. AQUA can assess TMAs using 
fluorescent tags to define 
tumors, localize sub-cellular 
compartments, and grade 
intensity of specific markers on a 
continuous scale.  
8. Quality of life assessment for 
men with PCa
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
9
4
STUDY DESIGN 
4.1
OVERALL DESIGN
We hypothesize that QC fermented soy is beneficial in adults with prostate cancer on the basis of prior 
anti-cancer activity in human prostate cancer cell lines.
This is a parallel group, double-blind, randomized, phase III clinical trial. The primary aim is to assess the 
efficacy of Q-CAN (QC) fermented soy vs. placebo in 72 adults with prostate cancer. Subjects will be 
randomized to one of two arms (n=72; 36 per arm), and stratified (low/high) based on Cancer of the 
Prostate Risk Assessment11 (CAPRA) score: 0-4=low/intermediate risk, 5-10=high risk). The two arms are:
1.
Intervention: Daily QC (two 12.5g packets/day) (~1 ounce/day) taken between the time of 
enrollment and radical prostatectomy.
2.
Control:  Daily (matched dose) placebo, taken between the time of enrollment and radical 
prostatectomy.  
 
This is a multi-site trial.  Clinical assessments (3 study visits) will take place either in the Yale Center for 
Clinical Investigation’s Research Outpatient Unit, or in LMH’s urology clinic space, or South County 
Hospital (SCH) urology clinic space (as determined by the referring physician’s location), at: 1) 
screening/baseline, 2) enrollment (~1-3 days after BL), and 3) just prior to prostatectomy, estimated at 
between 4 and 10 weeks from baseline/enrollment (see section 1.3 SOA).  Length of time in the study 
will vary for each subject, depending on how far out their prostatectomy will occur; all prostatectomies 
will be scheduled to occur between 4-10 weeks post-baseline.
To minimize bias, the Medical Informatics Group will handle randomization through Yale’s Clinical Trial 
Management System, OnCore® (Forte Research Systems, Inc., Madison, WI). The blinded study 
coordinator will access the OnCore® system to indicate eligibility status based on inclusion/exclusion 
criteria. The assignment will then be retrieved by a blinded OnCore® Statistician, who will perform 
randomization. Once the participant has been successfully randomized to a treatment arm, the 
statistician will send confirmation to the pharmacy for dispensing, and also inform the study 
coordinator.  Once made, the assignment is final and the participant will be analyzed in that group 
regardless of future events or information, in accordance with the intent-to-treat principle. 
For interim analysis details, refer to Section 9.4.6, Planned Interim Analysis.
4.2
SCIENTIFIC RATIONALE FOR STUDY DESIGN
The design and rationale for this study are informed by and based on the work of Lazarevic et al.5  
4.3
JUSTIFICATION FOR DOSE
Based on participant reports in the preliminary study, QC was both palatable and tolerable (only one 
participant withdrew), with no adverse effects besides some reports of mild gastrointestinal symptoms. 
Thus, the palatability and tolerability of the product dosing in the preliminary study (two 8-oz. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
10
bottles/day) serves, in part, as the basis for dosage in the proposed study. The product characterization 
(as described in Section 2.2, Background) further justifies dosing for the proposed study, as the 
laboratory analysis demonstrated that this dose contains 141 mg of genistin and 26 mg of genistein per 
8 oz. (240 ml) bottle. 
4.4
END OF STUDY DEFINITION
A participant is considered to have completed the study if he has completed all study visits (including 
participation in the weekly phone calls to assess daily IP intake), as shown in Section 1.3, Schedule of 
Activities. The end of the study is defined as completion of the last subject’s final study visit. 
5
STUDY POPULATION
5.1
INCLUSION CRITERIA
In order to be eligible to enter this study, an individual must meet all of the following criteria:
1) Histologically verified Prostate Cancer (at any stage) 
2) Age ≥18 years 
3) Scheduled to be treated by radical prostatectomy within the next 4-10 weeks
4) Understanding and willingness to provide consent 
5.2
EXCLUSION CRITERIA
An individual who meets any of the following criteria5 will be excluded from participation in this study:
1) Previous (within 6 months of enrollment) or concurrent hormonal therapy or chemotherapy; 
specifically, treatment with 5-alpha reductase inhibitors (finasteride and dutasteride).
2) History of hormone dependent malignancies
3) Concomitant thyroid disease or currently taking thyroid hormone replacement medication
4) Current high-dose soy consumption, micronutrient, or herbal supplements, on soy or vegetarian 
nutrition, or any other extreme dietary habits
5) Current or past history of any liver or pancreas disease
6) History of hypersensitivity to soy-containing products
7) Malabsorption conditions that might interfere with absorption of the investigational product 
5.3
LIFESTYLE CONSIDERATIONS
During this study, participants may maintain their current diet and level of physical activity to which they 
are accustomed, i.e., they will not be asked to abstain from small amounts of soy in their diet.  (At time 
of phone screening, individuals who reported current high-dose soy consumption, use of herbal 
supplements, or soy or vegetarian nutrition, or any other extreme dietary habits would have been 
excluded from participation.)
5.4
SCREEN FAILURES
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
11
Screen failures are defined as participants who consent to participate in the clinical trial but are not 
subsequently randomly assigned to the study intervention or entered in the study. A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure participants, to 
meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography, screen 
failure details, eligibility criteria, and any serious adverse event (SAE).
Individuals who do not meet the criteria for participation in this trial (screen failure) because of 
indecision about surgical treatment or temporary use of NSAIDS may be rescreened. Rescreened 
participants should be assigned the same participant number as for the initial screening.
5.5
STRATEGIES FOR RECRUITMENT AND RETENTION
Recruitment for this multi-site trial will take place in southern and southeastern Connecticut in the 
catchment areas of Yale University and Lawrence+Memorial Hospital (LMH), respectively, and in 
southern Rhode Island, South County Hospital’s service area. Primarily, Principal Investigator Dr. Michael 
Leapman and Site Principal Investigator Dr. Joseph Renzulli II will be drawing from their and fellow Yale 
School of Medicine urologic oncologist’s patient base meeting study eligibility criteria. Eligible patients 
of all ethnicities and races will be recruited without preference.
Positive post-biopsy prostate cancer patients of Drs. Leapman and Renzulli and the urologist Co-
Investigators will be identified to the Clinical Trials Manger, who will invite patients awaiting 
prostatectomy to meet in person for clinical screening in Yale Center for Clinical Investigation’s Church 
Street Research Unit (CSRU), or in LMH’s or SCH’s urology clinic (as determined by referring physician’s 
location).  The Clinical Trials Manger will thoroughly telephone screen interested persons to ensure 
eligibility (i.e., they meet no exclusion criteria) before inviting and scheduling them for a face-to-face 
informed consent and clinical screening at the CSRU or LMH, or SCH. 
If needed, the investigators may employ the services of the Yale Center for Clinical Investigation/Clinical 
and Translational Science Award (CTSA) for recruitment, including dedicated recruitment staff, 
community outreach personnel, as well as the use of the www.yalestudies.org website with targeted 
recruitment information.
The targeted enrollment (n=72) over the 3-year recruitment period will be met with an estimated 
accrual rate of 24 participants enrolled per year.  
As a thank you for their time, participants will be remunerated a total of $300 using the Bank of America 
reloadable card ePayment system through OnCore®, for consuming the study drink, providing blood 
samples, answering the questionnaire, and being available for phone check-in on a weekly basis.  $100 
will be given at Visit 1 and $200 will be given at Visit 2.  
6
STUDY INTERVENTION
6.1
STUDY INTERVENTION(S) ADMINISTRATION
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
12
6.1.1
STUDY INTERVENTION DESCRIPTION
The investigational product is Q-CAN® Plus (“QC”), a fermented soybean-derived phytochemical food 
supplement in liquid form. QC is a commercially available GRAS beverage; the active ingredient is 
soybean (22%).  The product’s primary constituents are the isoflavones genistin and daidzin (and 
respective metabolites genistein and daidzein). This trial will assess the efficacy of QC fermented soy in 
freeze-dried powdered form vs. placebo, in 72 adults with prostate cancer during the interim between 
biopsy and prostatectomy (4-10 weeks).  The placebo is a brown rice-based powder matching in color 
and consistency with the (active) soy intervention, and is flavored with the same natural chocolate 
flavor and sweetener, Siraitia grosvenorii (monk fruit) as the soy intervention powder.  
6.1.2
DOSING AND ADMINISTRATION
At Visit 1, participants will be given their allotment of assigned study drink.  One week of study drink 
equals 14 single dose packets. (Dose escalation or dose-ranging is not applicable to this trial.) Each 
participant will be dispensed 10 weeks’ worth of IP (referred to as a “kit”), a box containing 140 foil 
pouch packets. 
Participants randomized to the Intervention arm will orally consume two 12.5 g packets/day (~1 
ounce/day) of the fermented soy powder, reconstituted with 8 oz. of water or juice (per packet), taken 
between the time of enrollment and their final study visit (Visit 2), approximately 24-48 hours prior to 
prostatectomy.  Participants randomized to the Control arm will orally consume a matched daily dose of 
the placebo, reconstituted with 8 oz. of water or juice (per packet), taken between the time of 
enrollment and their final study visit (Visit 2), approximately 24-48 hours prior to prostatectomy.  
Participants will be instructed they may drink each daily portion all at once or throughout the day, as 
preferred. However, once the study drink has been prepared with liquid, any portion remaining requires 
refrigeration until consumed.  Ideally, the study drink is to be taken with food.  
Participants will keep a daily account (“Daily Log for IP Intake”) of when they consumed (or did not 
consume) their assigned study drink.  If they miss a dose, they will be instructed to record “0” on their 
daily log for any dose missed, and resume the following day with dosing as usual (i.e., they will not be 
instructed to “make up” the dose by consuming extra packets). 
6.2
PREPARATION/HANDLING/STORAGE/ACCOUNTABILITY
6.2.1
ACQUISITION AND ACCOUNTABILITY
Kits of packets containing the study intervention and control will be shipped from the manufacturer 
directly to the YNHH pharmacy and the SCH pharmacy.  Once the OnCore® statistician has informed the 
pharmacy of the participant’s randomization event and surgery date for prostatectomy, a member of 
the pharmacy team will generate the “prescription order”. The applicable pharmacy will dispense the 
appropriate kit to the clinical trials manager, who will then meet with the participant during Visit 1 to 
dispense it.  Participants will be instructed to return all packets for reconciliation count/compliance at 
Visit 2 (whether used or unused).  The clinical trials manager or designee will deliver the packets to the 
applicable pharmacy for final documentation and final disposition/destruction. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
13
6.2.2
FORMULATION, APPEARANCE, PACKAGING, AND LABELING
The intervention product is Q-CAN® Plus, a fermented soybean-derived phytochemical liquid food 
supplement in a freeze-dried version. Q-CAN® is a commercially available GRAS beverage that has been 
marketed in China since 1985 and in the United States since 1991.  In the US, it is marketed as a food, 
under Fujian Yang Zhenhua 851 Bio-Science Co., Ltd., registration number 17334630796.  The active 
ingredient is soybean (22%), and primary constituents of the formulation are isoflavones genistin, 
daidzin genistein, and daidzein.  The freeze-dried powder consists of fermented soy (78.2%), soy extract 
(1.8%), natural chocolate flavor (18%), and Siraitia grosvenorii (2%).              
                    
The placebo product for this trial will be a brown rice flour-based powder, matching in color and 
consistency with the intervention product.  The placebo will contain the same flavoring (natural 
chocolate flavor, 18%) and sweetener (Siraitia grosvenorii, 2%) as the intervention, for dual purposes of 
matching taste (to the greatest degree possible) and masking the difference in flavor between 
fermented soy and brown rice powders. 
Fujian Yang Zhenhua 851 Bio-Science Co., Ltd./BESO Biological Research Center, Inc., will manufacture 
the intervention and placebo products.  The immediate packaging for both will be a sealed foil pouch, as 
shown below: 
 
6.2.3
PRODUCT STORAGE AND STABILITY
From an environmental standpoint, using an intervention product and placebo in powdered form 
imposes minimum storage requirements. To prevent moisture and contaminants from degrading the 
products, seal integrity of the foil packaging (primary container) for both products will be assessed at 
stability testing.  Cardboard packaging (secondary container) will enclose both products. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
14
The foil packets containing the intervention product and placebo product will be stored in a dedicated 
space at the YNHH pharmacy and at the SCH pharmacy in a temperature- and humidity-controlled room.  
For participants being seen in LMH, the YNHH pharmacy will currier the kits of IP to LMH pharmacy the 
day of or the day prior the scheduled IP dispensing visit. 
6.2.4
PREPARATION
Participants will be instructed to reconstitute contents of 2 packets per day by pouring the powder into 
8 oz. of water or juice (per packet) and mixing well before drinking.  Also refer to section 6.1.2, Dosing 
and Administration.
6.3
MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING
Description of randomization and blinding procedures:  A single randomization scheme for the study will 
be generated. This scheme will be written and validated by a system programmer in the Medical 
Informatics Group, Yale Center for Clinical Investigation (YCCI)/NIH CTSA, and will be incorporated into 
Yale’s Clinical Trial Management System, OnCore®. Participants will be randomized to one of two arms, 
intervention or placebo control (n = 72; allocated in a 1:1 ratio to 36 per arm). Allocation will be 
concealed through restrictions within the OnCore® system, where neither the block nor block size can 
be revealed to study personnel. The randomization scheme is stratified by risk level (0-4 = 
low/intermediate risk, 5-10 = high risk), which is based on the Cancer of the Prostate Risk Assessment 
(CAPRA) score.  Once made, the assignment is final and the participant will be analyzed in that group 
regardless of future events or information, in accordance with the intent-to-treat principle.
Plans for the maintenance of trial randomization codes and appropriate blinding: After review of 
eligibility criteria, the blinded clinical trials manager will access the OnCore® system to enter the 
participant’s screening/baseline data and indicate study eligibility status, thus initiating randomization. 
Once a participant’s study status is updated to “Eligible”, this indication will then be retrieved by a 
blinded, specified OnCore® statistician who will perform the randomization assignment through 
OnCore®.  The statistician will also serve as liaison to the dispensing pharmacy by sending confirmation 
via email to either the Yale-New Haven Hospital pharmacists or the South County Hospital pharmacist, 
informing them of the randomization event, in order for them to release the order for preparing the 
assigned IP for dispensing. The statistician will also inform the clinical trials manager when a participant 
has been randomized, giving an indication when the IP may be obtained from the pharmacy. The YNHH 
and SCH pharmacists will be necessarily unblinded to participant’s randomization status.  LMH 
pharmacists, however, will remain blinded; YNHH pharmacy will simply currier the kits needed for 
subject visits at LMH.  
Circumstances in which the blind would be broken for an individual would be in the event of an SAE. 
Unblinding of all participants would occur only by the PI, with concern for a suspected or substantiated 
SAE associated with the intervention or placebo. 
Problems anticipated:  Compared to brown rice, the odor of fermented soy is distinctive and strong.  The 
potential for unblinding of study personnel would exist in handling participants’ used/opened pouches. 
For this reason, participants will be asked to return their packets for accountability and reconciliation in 
a large, re-sealable plastic bag, which will be supplied for each kit.  
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
15
Intervention and control/placebo are as indistinguishable as possible: Foil pouch labeling for intervention 
and placebo will be identical, with the exception of lot number.  The manufacturer will communicate 
directly with the pharmacy to ensure the dispensing pharmacists can distinguish between active and 
control packets.  
Measures to prevent unblinding by laboratory measurements: Unblinding by laboratory measurements is 
highly improbable as participants with CAPRA scores at low- and high-risk levels (stratification scheme) 
will be randomized into each of the study’s two arms.  
Plans for managing and reporting inadvertent unblinding:  All inadvertent unblinding will be reported to 
the PI.  Unblinded patients would be censored from analysis and excluded from participation. 
6.4
STUDY INTERVENTION COMPLIANCE
Using the paper form, “Daily Log for IP Intake”, participants will keep a daily record of their assigned 
study drink intake, to both facilitate reconciliation and reduce recall bias when queried each week 
during phone assessment. The Clinical Trials Manger or a member of the study team will call participants 
on a weekly basis to assess, log, and track safety, tolerance and adherence to study drink consumption.  
An eCRF in the OnCore® system will be used to document and manage weekly data on each participant, 
regarding the number of doses missed per week and the reason(s) why.  Compliance with study 
procedures will be assessed weekly for every participant.  Participants will be in compliance if they if 
they receive at least one dose per day for an average of greater than 50% of study days.
6.5
CONCOMITANT THERAPY
Immediately prior to screening/baseline, participants’ concomitant prescription medications, over-the-
counter medications, and supplements are reviewed by the Clinical Trials Manager in Epic EMR 
(electronic medical record, Epic Systems Corporation) to verify exclusion criteria. Thereafter, at all visits 
and weekly telephone calls, participants are asked whether there have been any changes in their 
medications since their previous encounter with the Clinical Trials Manager or designee.  
7
STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL
7.1
DISCONTINUATION OF STUDY INTERVENTION  
A participant’s elective discontinuation from soy or placebo intake means discontinuation from active 
participation in the study.  Study personnel will attempt to collect any remaining study procedure data 
as the participant’s (final) post-consumption data.  
If a clinically significant finding is identified (including, but not limited to change in eligibility criteria from 
baseline) after enrollment, the Principal Investigator or qualified designee will determine if any change 
in participant management is needed. Any new clinically relevant finding will be reported as an adverse 
event (AE).
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
16
Data to be collected at the time of study intervention discontinuation will include data collected at date 
of study initiation (date of first participant enrollment) through to the date of last participant follow-up. 
Participants who withdraw prior to study termination will be discussed in the clinical study report. The 
trial database will be closed/frozen and be considered ready for final analysis after all queries and edits 
have been reviewed and applied.
No new health information will be gathered after the date of participant withdrawal/discontinuation.  
Information that has already been gathered may still be used until the end of the study, as necessary to 
insure the integrity of the study and/or study oversight.  
7.2
PARTICIPANT DISCONTINUATION/WITHDRAWAL FROM THE STUDY
Participants are free to withdraw from participation in the study at any time upon request.
Compliance with study requirements will be assessed throughout the study.  Participants may be 
withdrawn from the study if they do not agree or adhere to study requirements listed in section 1.3, 
Schedule of Activities.  
An investigator may discontinue or withdraw a participant from the study for the following reasons:

Significant study intervention non-compliance 

Any clinical adverse event (AE), intercurrent illness, or other medical condition or situation 
occurs such that continued participation in the study would not be in the best interest of the 
participant

Disease progression which requires discontinuation of the study intervention

Development of any exclusion criteria (either newly developed or not previously recognized) 
that precludes further study participation

Participant unable to consume fermented soy or placebo for 15 days. 
The reason for participant discontinuation or withdrawal from the study will be recorded in the OnCore® 
electronic data capture system.  Subjects who sign the informed consent form and are randomized but 
do not receive the study intervention may be replaced.  Participants who sign the informed consent 
form, are randomized, and receive the study intervention, but either subsequently withdraw, or are 
withdrawn/discontinued from the study, will be replaced. 
7.3
LOST TO FOLLOW-UP
A participant will be considered lost to follow-up if he fails to return for Visit 1 or Visit 2 and is unable to 
be contacted by study staff. 
The following actions will be taken if a participant fails to return to the clinic for a required study visit:

Study staff will attempt to contact the participant the day the appointment was missed to 
reschedule the missed visit as soon as possible, and will counsel the participant on the 
importance of maintaining the assigned visit schedule and ascertain if the participant wishes to 
and/or should continue in the study.
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
17

Before a participant is deemed lost to follow-up, the investigator or clinical trials manager will 
make every effort to regain contact with the participant (where possible, 3 telephone calls and 
email attempts). These contact attempts will be documented in the participant’s study file. 

Should the participant continue to be unreachable, he will be considered to have withdrawn 
from the study with a primary reason noted and date of lost to follow-up recorded in the 
participant’s study file and in OnCore®.
8
STUDY ASSESSMENTS AND PROCEDURES
8.1
EFFICACY ASSESSMENTS 
Sequence of events to occur during the screening process and any decision points regarding participant 
eligibility: Positive post-biopsy prostate cancer patients of the PI and other Yale School of Medicine 
referring urologists will be invited to participate in the study. The patients will be identified to the 
clinical trials manager, who will invite them to meet in person for clinical screening at the Yale Center for 
Clinical Investigation’s outpatient research clinic, the CSRU (Church Street Research Unit), or LMH’s or 
SCH’s urology clinic area (determined by referring physician’s location), as they await prostatectomy. An 
initial phone screening will take place to first, to assess the patient’s interest in participating, discuss 
study details, and determine whether any unknown exclusion criteria exist before scheduling the 
screening visit.  The referring urologist determines their patients’ eligibility for study entry at time of 
referral.
Time frame prior to enrollment within which screening procedures/evaluations must be performed:  The 
Screening/Baseline Visit will take place as soon after the patient’s prostatic biopsy as possible.  Ideally, 
study enrollment will occur within 3-4 days after the Screening/Baseline Visit, as patients will have been 
given their date for prostatectomy, and the interim between biopsy and surgery is the period of the 
intervention.  
In the event a randomized patient’s prostatectomy is postponed (whether by patient preference or 
otherwise) beyond 180 days from the initial Screening/Baseline visit, the patient must be re-screened to 
have new baseline laboratory values established if he wishes to resume participation in the study.
Procedures and evaluations to be done as part of the study to support the determination of efficacy 
include:
Biological specimen collection and laboratory evaluations – Screening/baseline and end-of-study 
serology (final study visit, Visit 2 - time of admission for surgery, 24 hours after ingestion of the last 
study dose) includes: 
PHI (prostate health index, which gives total and % free PSA - prostate-specific antigen), ESR 
(erythrocyte sedimentation rate), CBC with Diff (complete blood count with differential), CMP 
(comprehensive metabolic panel), testosterone (total, bioavailable and free), CRP (C-reactive 
protein), lipase, lipid panel, amylase, TSH (thyroid stimulating hormone), estrogen, IGF-1 (insulin-like 
growth factor), IGFBP-1, IGFBP-2, and IGFBP-3 (insulin-like growth factor binding proteins).  

Nursing staff and phlebotomists at all sites are trained and certified in standard phlebotomy 
techniques.

Total volume of blood to be drawn per subject visit is approximately 20-30 cc.
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
18

A single, central processing laboratory (YNHH) will be used for all sites, to decrease 
variability in test results for the primary outcome, PSA.
Special assays or procedures required – The following pathological analyses and assays will be 
performed after the study has closed to enrollment: 

Pathological investigation of the removed prostate gland, analyzing any modulation of 
prostate cancer grade (Gleason score) and disease progression (CAPRA-S) compared to 
preoperative biopsies, volume of gland and of biopsy-proven, index prostate cancer lesion, 
and extent (involvement of surgical margins and extraprostatic extension) of clinical and 
pathological tumor stage and degree of tumor focality.

Telomere length (TeloTAGGG™ Telomere Length Assay) will be used to estimate telomeric 
DNA length from prostate cancer tissue.  

Automated quantitative (AQUA) immunofluorescence analysis of markers of prostate cancer 
aggressiveness on a tissue microarray, using fluorescent tags to define tumors, localize sub-
cellular compartments, and grade intensity of specific markers. 

Instances when curative treatment plan changes – Should an enrolled participant’s course of 
treatment change in that he would not undergo prostatectomy (such as undergoing radiation 
therapy instead), with the treating urologist’s approval, the participant may elect to remain in the 
study, continue daily IP dosing and attend his final subject visit as scheduled.  The primary outcome 
of the study is prostate-specific antigen (PSA), which can be obtained post-IP consumption 
regardless. It is accepted that the secondary outcomes (AQUA, CCP and telomere assay) comparing 
biopsied tissue with tissue from the resectioned prostate would be lost in these rare instances when 
individuals do not undergo surgical removal of their prostate.  

Administration of questionnaires, instruments and patient-reported outcomes - Participants will be 
asked to complete: 

An inventory of soy-containing foods they have consumed within the past month at 
Screening/Baseline.

Pre/post FACT-P (Functional Assessment of Cancer Therapy - Prostate), a validated, 39-item 
questionnaire that measures health-related quality of life specific to men with prostate 
cancer, and assesses well-being in four domains (physical, social/family, emotional, and 
functional). 

Participants will be given thorough dosing instructions for consuming the study drink, and 
will be asked to complete a daily dosing diary.
Follow-up procedures after administration: The final participant assessments will occur at Visit 2, 
approximately 24-48 hours prior to prostatectomy.  No further follow-up by research personnel is 
planned at this time; patients will be followed by their treating urologist for clinical care. 
8.2
SAFETY AND OTHER ASSESSMENTS
Sequence of events to occur during the screening process and any decision points regarding participant 
eligibility: refer to Section 8.1, Efficacy Assessments
Time frame prior to enrollment within which screening procedures/evaluations must be performed:  refer 
to Section 8.1, Efficacy Assessments 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
19
Procedures and evaluations to be done as part of the study to support the determination of safety 
include:

Biological specimen collection and laboratory evaluations - 

Screening/Baseline Serology (to ensure patients’ laboratory results are within 
acceptable range for study participation):  CRP (C-reactive protein), lipase, lipid panel, 
amylase, TSH (thyroid stimulating hormone), ESR (erythrocyte sedimentation rate), CBC 
with Diff (complete blood count with differential), and CMP (comprehensive metabolic 
panel). These tests will be repeated at Visit 2 to ensure deleterious changes have not 
occurred and that patients’ laboratory results are within acceptable range prior to 
prostatectomy (refer to Section 1.3, SOA for complete serology list).  

Nursing staff and phlebotomists at all sites are trained and certified in standard phlebotomy 
techniques.

Total volume of blood to be drawn at Screening/Baseline and at Visit 2 is approximately 20-
30 cc.

Administration of questionnaires, instruments and patient-reported outcomes – refer to Section 
8.1, Efficacy Assessments

Counseling procedures, including any dietary or activity considerations - During this study, 
participants may maintain their current diet and level of physical activity to which they are 
accustomed, i.e., they will not be asked to abstain from small amounts of soy in their diet.  (At time 
of phone screening, individuals who reported current high-dose soy consumption, use of herbal 
supplements, or soy or vegetarian nutrition, or any other extreme dietary habits – or soy allergy or 
sensitivity – would have been excluded from participation.)   Participants will be given thorough 
dosing instructions for consuming the study drink, and will be asked to complete a daily dosing 
diary.

Assessment of study intervention adherence - Safety, tolerability and adherence to IP intake will be 
assessed through participant self-report since baseline, via weekly phone calls to participants until 
they complete the study (Visit 2). If any AEs are noted during the phone assessments or study visits, 
they will also be recorded in OnCore® using an Adverse Events eCRF, including actions taken to 
resolve the AE.
8.3
ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS
8.3.1
DEFINITION OF ADVERSE EVENTS (AE)
An adverse event is any untoward medical occurrence associated with the use of an intervention in 
humans, whether or not considered intervention-related (21 CFR 312.32 (a)).  Further, an AE is any 
unfavorable and unintended or abnormal laboratory finding, symptom, or disease temporally associated 
with the use of a medical treatment or procedure, regardless of whether it is considered related to the 
medical treatment or procedure.
8.3.2
DEFINITION OF SERIOUS ADVERSE EVENTS (SAE) 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
20
An adverse event (AE) or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes: death, a life-threatening adverse 
event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant 
incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital 
anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or 
require hospitalization may be considered serious when, based upon appropriate medical judgment, 
they may jeopardize the participant and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do 
not result in inpatient hospitalization, or the development of drug dependency or drug abuse (21 CFR 
312.32 (a)).
For this trial, adverse events meeting the definition of serious will be collected on all participants, 
regardless of their association with the study treatment, from the time of randomization to the end of a 
participant’s follow-up.
8.3.3
CLASSIFICATION OF AN ADVERSE EVENT
8.3.3.1 SEVERITY OF EVENT
For adverse events (AEs) not included in the protocol defined grading system, the following guidelines 
will be used to describe severity. 
•
Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities. 
•
Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Moderate events may cause some interference with functioning.
•
Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life-threatening or 
incapacitating.  Of note, the term “severe” does not necessarily equate to “serious”. 
8.3.3.2
RELATIONSHIP TO STUDY INTERVENTION
All adverse events (AEs) must have their relationship to study intervention assessed by the clinician who 
examines and evaluates the participant based on temporal relationship and his/her clinical judgment. 
The degree of certainty about causality will be graded using the categories below. In a clinical trial, the 
study product must always be suspect. 
•
Related – The AE is known to occur with the study intervention, there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention and the AE.
•
Not Related – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention 
and event onset, or an alternate etiology has been established.
8.3.3.3
EXPECTEDNESS 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
21
The principal investigator will be responsible for determining whether an adverse event (AE) is expected 
or unexpected. As with our preliminary safety/tolerability study of fermented soy consumption in 
healthy volunteers (N=20) we would expect that mild, intermittent gastrointestinal (GI) symptoms 
(nausea, stomach pain, diarrhea, and/or distension) could occur in a minority of participants, and would 
more likely become known after the first few doses, at the beginning of the study.  While subjects will 
be screened for known allergy to soy, there is a risk of allergic reaction. An AE will be considered 
unexpected if the nature, severity, or frequency of the event is not consistent with symptoms as 
described here. 
8.3.4
TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW-UP
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the attention of 
study personnel during study visits and interviews of a study participant presenting for medical care, or 
upon review by a study monitor.
All AEs including local and systemic reactions not meeting the criteria for SAEs will be captured on the 
appropriate eCRF in OnCore®.  Information to be collected includes event description, time of onset, 
clinician’s assessment of severity, relationship to study product (assessed only by those with the training 
and authority to make a diagnosis), and time of resolution/stabilization of the event. All AEs occurring 
while on study must be documented appropriately regardless of relationship. All AEs will be followed to 
adequate resolution.
Any medical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE.  However, if the study participant’s condition deteriorates at any 
time during the study, it will be recorded as an AE. 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed. AEs characterized as intermittent require documentation of 
onset and duration of each episode.
The clinical trials manager will record all reportable events (AEs and SAEs) with start dates occurring any 
time after informed consent is obtained until the last day of study participation.  At each study visit, the 
clinical trials manager will inquire about the occurrence of AE/SAEs since the last visit.  Events will be 
followed for outcome information until resolution or stabilization.
8.3.5
ADVERSE EVENT REPORTING 
An assessment of treatment relatedness is required for each event reported.  The project’s clinical team 
will generate tabulations of any AEs in the OnCore® system. A summary of all AEs believed to be related 
to the study intervention will be reviewed by the PI, who will then coordinate reporting of these events 
to the DSMC. 
8.3.6
SERIOUS ADVERSE EVENT REPORTING 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
22
An assessment of treatment relatedness is required for each event reported.  The project’s clinical team 
will generate tabulations of SAEs in the OnCore® system. A summary of all SAEs believed to be related to 
the study intervention will be reviewed by the PI and co-investigators. 
Unexpected SAEs that occur during the conduct of the trial will be expeditiously reported (within 24 
hours of becoming known) by the Clinical Trials Manager to the study sponsor.  The Sponsor-Investigator 
will report to the FDA (if deemed appropriate), as specified in the protocol.
Data on fatal or life-threatening SAEs will be reported by the Sponsor-Investigator, if required, to 
regulatory authorities as per 21 CFR 312.32(c)(2) as soon as possible but in no case later than 7 calendar 
days after initial receipt of the information (treatment assignment blinded) and will be tabulated and 
presented to the DSMC (treatment assignment blinded or unblinded as per DSMC decision).
In addition, the Sponsor-Investigator will notify FDA in an Investigational New Drug (IND) safety report 
of potential serious risks, from clinical trials or any other source, as soon as possible, but in no case later 
than 15 calendar days after the Sponsor-Investigator determines that the information qualifies for 
reporting.
8.3.7
REPORTING EVENTS TO PARTICIPANTS 
Participants in this RCT will be informed should any SAEs develop during the course of the study, which 
would affect their willingness to participate.  SAEs (and any significant new findings) will require urgent 
contact with current participants. Depending on the circumstances of the SAE, this may be extended to 
include informing previous and potential participants. Communications with each participant will be 
documented in their research record and in the Adverse Event eCRF in OnCore®.  AEs will be evaluated 
individually as to whether they are product/study-related. If so, communications with each individual 
affected will be documented in the same manner.  
Frequent opportunities will exist for an assessment of safety/tolerability, as participants will be called on 
a weekly basis throughout the intervention period of the study. Management (corrective action) of 
incidental findings will follow according to those outlined in Section 8.4.1, Definition of Unanticipated 
Problems (UP) and Section 8.4.2, Unanticipated Problem Reporting.
A description of this clinical trial and study-related results on an aggregate level will be will be available 
on the ClinicalTrials.gov clinical trial registry website.
8.4
UNANTICIPATED PROBLEMS
8.4.1
DEFINITION OF UNANTICIPATED PROBLEMS (UP)
The Office for Human Research Protections (OHRP) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets all of the 
following criteria:
•
Unexpected in terms of nature, severity, or frequency given (a) the research procedures that are 
described in the protocol-related documents, such as the IRB-approved research protocol and 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
23
informed consent document; and (b) the characteristics of the participant population being 
studied;
•
Related or possibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and
•
Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.
This protocol presents minimal risks to the participants.  Unanticipated Problems Involving Risks to 
Subjects or Others (UPIRSOs), including adverse events, are not anticipated. However, corrective actions 
or changes that may be considered in response to an Unanticipated Problem include:
•
Modification of inclusion or exclusion criteria to mitigate the newly identified risks
•
Implementation of additional safety monitoring procedures
•
Suspension of enrollment of new participants or halting of study procedures for enrolled 
participants 
•
Modification of informed consent documents to include a description of newly recognized risks
•
Provision of additional information about newly recognized risks to previously enrolled 
participants.
8.4.2
 UNANTICIPATED PROBLEM REPORTING 
Unanticipated Problems Involving Risks to Subjects or Others (UPIRSOs), including adverse events, are 
not anticipated in this study, as it presents minimal risks to participants.  In the unlikely event that such 
events occur, “reportable events” (events that are serious or life-threatening and unanticipated) or 
events that are anticipated but may be occurring with a greater frequency than expected (whether they 
are possibly, probably, or definitely related), or any UPIRSOs that may require a temporary or 
permanent interruption of study activities, will be reported immediately (if possible), followed by a 
written report to the IRB, using the appropriate forms from the Yale Human Research Protection 
Program website as per their written policies and procedures.  The appropriate funding and regulatory 
agencies will also be notified. The principal investigator will apprise fellow investigators and study 
personnel of all UPIRSOs and adverse events that occur during the conduct of this research project via 
email, as the PI would review them all. 
The UP report will include the following information:
•
Protocol title, IRB/Human Investigation Committee protocol number, and name of PI
•
A detailed description of the event, incident, experience, or outcome 
•
An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an unanticipated problem
•
A description of any changes to the protocol or other corrective actions that have been taken or 
are proposed in response to the UP
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
•
UPs that are serious adverse events (SAEs) will be reported to the IRB as per their written 
policies and procedures and to the study sponsor immediately (within 24 hours) upon the 
principal investigator becoming aware of the event. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
24
•
Any other UPs will be reported to the IRB as per their written policies and procedures and to the 
study sponsor within 5 calendar days of the investigator becoming aware of the problem. 
The protocol’s research monitor(s), e.g. Cancer Center Protocol Review Committee (PRC), Yale Cancer 
Center Data and Safety Monitoring Committee (DSMC) reviews entries of unanticipated problems in 
OnCore® at each meeting.
8.4.3
REPORTING UNANTICIPATED PROBLEMS TO PARTICIPANTS 
The principal investigator or study personnel will inform participants about UPs which may affect them 
on an individual basis via preferred their means of contact, whether by phone, email or in person.  
9
STATISTICAL CONSIDERATIONS 
 
9.1
STATISTICAL HYPOTHESES

Primary Efficacy Endpoint(s): Serum prostate-specific antigen (PSA)
The study is designed as a superiority trial; the primary comparison will be the main effects of QC vs. 
Placebo. This comparison will be made by assessing the change in serum PSA values (Time of admission 
for surgery – Baseline) of participants in the two study arms. A two-tailed p-value will be used with a 
Type I error of 0.05 as the level of statistical significance. 

Secondary Efficacy Endpoint(s):
Variables assessed pre and post-surgery are classified as secondary endpoints:
1. Volume of prostate gland
2. Volume of biopsy-proven, index prostate cancer lesion 
3. Prostate cancer tissue telomeric DNA length 
4. Cell cycle progression (CCP) score assessment of prostate cancer mRNA from prostate cancer
                   tissue 
5. Specific marker changes on PCa tissue microarrays (TMAs) using automated quantitative
    analysis (AQUA)
6. Gleason score compared to preoperative biopsies 
7. Quality of life (FACT-P)
8. CAPRA-S (post-surgical CAPRA score)
9.2
SAMPLE SIZE DETERMINATION
The sample size calculation was based on the following assumptions: 
PSA difference*= 15 units
Standard Deviation = 20.3
Power (Type II error) = 0.8
Type I error (two-sided) = 0.05 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
25
Repeated measures analysis design
Estimate of difference informed by results from Lazarevic et al.5 
Interim Monitoring:
The use of the Peto method for the interim analysis (alpha level=0.001) would not necessitate any 
consideration for sample size adjustment.
9.3
POPULATIONS FOR ANALYSES
Intention-to-treat (‘as randomized’) analyses will be performed on all randomized participants. Duration 
of treatment will be taken into account in the analysis.
Per-protocol (‘as-treated’) analysis will also be carried out; assessment of treatment adherence will be 
based on self-reported reporting during phone follow-up calls.
The Safety Analysis dataset will include participants who took at least one dose of study medication. 
9.4
STATISTICAL ANALYSES
9.4.1
GENERAL APPROACH   
Categorical data will be presented as counts and percentages. Continuous variables will be presented 
using mean with standard deviation and median with IQR. Graphical presentations will also be made as 
appropriate. 
Two-tailed, Type I error of 0.05 and 95% Confidence intervals will be used in analyses.
The CAPRA score level (low/medium vs high) will be used to run a stratified primary outcome analysis. 
Other variables will be considered later in the SAP for use as covariates in subsequent analyses.
Normality of distributions of continuous variables will be assessed and transformations (e.g. log, square 
root) will be considered, as appropriate, to normalize not normal distributions. In the event that 
normality cannot be achieved, nonparametric tests will be employed.
9.4.2
ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)
The primary outcome is change in serum PSA. This is the difference between the PSA value at baseline 
and the value at the time of admission for surgery (prostatectomy). 
‘Baseline’ is defined as the date that an eligible participant enrolls in the trial; randomization will occur 
within 3 days of baseline assessment. If no measurement is available in this 3-day window, the first 
measurement after randomization BUT before the date of treatment initiation and up to day 7, will be 
defined as baseline. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
26
Repeated measures analysis or linear mixed models analysis will be used to assess whether the mean 
change in PSA from pre to post-treatment differs in the two groups.  This can be achieved by measuring 
the (time by group) interaction term in a repeated measures ANOVA.
In secondary analysis of the primary outcome, the difference in PSA mean level at post-
intervention/pre-surgery between the two groups will be assessed using ANCOVA and adjusting for pre-
intervention/baseline values. This analytical approach will test whether the QC group has a higher PSA 
mean level following treatment. Adjusting for pre-treatment/baseline PSA level ensures that any post-
treatment differences are a consequence of treatment, and not a result of some random effect from the 
pre-treatment differences between the groups. In addition, variation in the post-treatment means 
stemming from the variation introduced from the pre-treatment participant starting point.
Stratified analysis (low/medium vs. high CAPRA score) will also be carried out.
9.4.3
ANALYSIS OF THE SECONDARY ENDPOINT(S)  
A number of secondary outcomes will be compared between the two trial arms.
A. Assessed pre and post-surgery
Continuous variables:
1. Volume of gland
2. Volume of biopsy-proven, index prostate cancer lesion 
3. Prostate cancer tissue telomeric DNA length 
4. Cell cycle progression score assessment of prostate cancer mRNA from prostate cancer tissue 
Analysis will be carried out using linear mixed models to assess whether mean changes (pre to post-
surgery) differs between the two groups. 
Ordinal variables:
1. Gleason score compared to preoperative biopsies 
2. Quality of life (FACT-P) 
The Wilcoxon Signed Rank test will be used to analyze these variables.
B. Assessed post-surgery
Continuous variables
1. Automated quantitative (AQUA) immunofluorescence analysis of markers of prostate cancer 
aggressiveness on a tissue microarray 
2. CAPRA-S11 post-surgical score (a validated risk stratification tool incorporating PSA, 
pathologic Gleason score, surgical margin status, extracapsular extension, seminal vesicle 
extension, lymph node status (0-12 points)
Post-surgery comparisons of continuous secondary outcomes between the two study groups will be 
carried out using parametric (t-test) or non-parametric (Wilcoxon Rank Sum) as deemed appropriate 
(based on normality of distribution). 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
27
Categorical variables
1. Degree of tumor focality 
Chi-square methods will be used to analyze this variable.
C. Assessed weekly for the duration of the study
1. Adverse events 
The percentage and rate of adverse events will be compared between the two groups. 
2. Adherence: Number of doses missed (assessed weekly from baseline to final visit) 
Repeated measures/longitudinal analysis will be used to analyze adherence to QC.
9.4.4
SAFETY ANALYSES   
Safety data will be collected as per definitions established in Section 8.3.2, Definition of Adverse Event 
(AE) and Section 8.3.2, Definition of Serious Adverse Event (SAE). 
For this trial, adverse events meeting the definition of serious will be collected on all participants, 
regardless of their association with the study treatment, from the time of randomization to the end of a 
participant’s follow-up. Attribution of the AE/SAE will also be presented in the Safety tables. In addition, 
those AE/SAE that led to study discontinuation will be presented in a separate table.
Safety tables will be generated for AE and SAE, overall and by treatment arm. Data will be presented at 
the event level as well as the patient level, i.e., AE/SAE and number of participants with AE/SAE. 
The OnCore® clinical trial management system uses the Common Terminology Criteria for Adverse 
Events (CTCAE, v4.0) to grade AE/SAE.  Since CTCAE Version 4.0 in May 2009, all CTCAE terms are 
MedDRA lowest level terms.
9.4.5
BASELINE DESCRIPTIVE STATISTICS  
In order to assess the adequacy of randomization, participant baseline characteristics among the 
treatment groups (demographics, laboratory measurements) will be tabulated and evaluated using 
descriptive statistics (mean, median, IQR) and graphs. Baseline characteristics that are determined as 
not equally distributed between the treatment groups will be considered for covariate adjustment in 
order to determine their impact on treatment comparisons.
9.4.6
PLANNED INTERIM ANALYSES    
An interim analysis will be carried out when 50% of the information on the primary outcome has been 
collected i.e. after post-prostatectomy PSA has been assessed for 36 participants. The interim analysis 
will be carried out using the conservative Peto method (p=0.0001).  The interim monitoring analysis will 
be for efficacy and will be provided to the DSMC by the unblinded trial biostatistician. After consultation 
with the DSMC, outcome data will be presented either with a different labeling notation for the 
treatment arm (e.g. A/B) or with clear indication of treatment group assignment. If statistical superiority 
is achieved (p<0.0001) the DSMC would be requested to provide a recommendation of premature 
termination of the trial due to efficacy. In addition, the DSMC would be at liberty to request conditional 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
28
power estimates in the event effect size assumptions used in the initial sample size estimation are not 
met.  
The investigators (on an on-going basis), the Study Monitor (see 10.1.7, Clinical Monitoring), and the 
DSMC (at its regular meetings) will closely monitor study progress, and individual patients will be closely 
monitored for signs and reports of adverse reactions. The investigators will conduct safety reviews at 
monthly intervals. During the review process the PI and investigators will evaluate whether the study 
should continue unchanged, require modification/amendment, continue or close to enrollment. Either 
the PI, or the Yale Human Research Protection Program (IRB), following consultation and 
recommendation from the DSMC, have the authority to stop or suspend the study or require 
modifications.
9.4.7
SUB-GROUP ANALYSES   
Currently, sub-group (using demographic and/or baseline variables) analyses of primary or secondary 
endpoints are not planned. This will be re-assessed, as necessary, in the SAP and sub-group analyses will 
be defined a prior to database lock. 
9.4.8
TABULATION OF INDIVIDUAL PARTICIPANT DATA   
For analytical purposes, participants will be counted in the group to which they were randomized, i.e. 
intent-to-treat analysis.
Individual participant level data will be presented only in the case of safety data monitoring and as 
requested by the DSMC and/or IRB.
9.4.9
EXPLORATORY ANALYSES   
The association of certain baseline variables with changes in serum PSA will be explored. Such analyses 
will evaluate change in PSA from baseline (at each time point and over the whole study period). 
Additional exploratory analysis will be carried out to compare the two trial arms in terms of the 
proportion of participants who achieve a 15% reduction in PSA. 
10
SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS
10.1 REGULATORY, ETHICAL, AND STUDY OVERSIGHT CONSIDERATIONS
10.1.1 INFORMED CONSENT PROCESS
10.1.1.1 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS
A consent form, describing in detail the study intervention, study procedures, and risks will be given to 
the participant as written documentation of informed consent, required prior to administering any study 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
29
procedures.  The “Compound Authorization and Consent for Participation in a Research Project” is 
submitted with this protocol.
10.1.1.2 CONSENT PROCEDURES AND DOCUMENTATION
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. The consent form will be Yale IRB-
approved and the participant will be asked to read and review the document.  The principal investigator 
or clinical trials manager will explain the research study to the individual and answer any questions that 
may arise. A verbal explanation will be provided in terms suited to the individual’s comprehension of the 
purposes, procedures, and potential risks of the study and of their rights as research participants.  
Investigators will determine the ability and capacity of individuals to give consent by questioning during 
the process of consent.  Potential participants will be asked, “Could you explain to me what we are going 
to ask you to do in this study?  This will help me to be sure that you understand the research,” as well 
as, “What more would you like to know about this study?”
Participants will have the opportunity to carefully review the written consent form and ask questions 
prior to signing. The participant will sign the informed consent document prior to any procedures being 
done specifically for the study. Participants will be informed that their participation is voluntary and that 
they may withdraw from the study at any time, without prejudice.  A copy of the informed consent 
document will be given to each participant for his records. The informed consent process will be 
documented in the Clinical Trial Management System, OnCore® (including the date and protocol version 
number), and the paper consent form signed, before the participant undergoes any study-specific 
procedures. A PDF of each signed consent form will be uploaded to OnCore® in the study’s ‘Documents’ 
tab.  An electronic screening log in OnCore® will be used to document study eligibility status/reasons for 
ineligibility.   Reasons for non-participation of eligible candidates is kept electronically in a password-
protected Excel file on an encrypted server. All participants will be informed that their participation is 
voluntary and they have the option of not participating, or of stopping at any time during the study. 
The rights and welfare of the participants will be protected by emphasizing to them that the quality of 
their medical care will not be adversely affected if they decline to participate in this study.
As needed, the consent document will be translated into Spanish versions for Spanish-speaking 
individuals.  Spanish version consent documents will be submitted to the HIC for review and approval 
before administration.  And, as needed, we will utilize bilingual translators for the informed consent 
process.
10.1.2
STUDY DISCONTINUATION AND CLOSURE
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be 
provided by the suspending or terminating party.  If the study is prematurely terminated or suspended, 
the Principal Investigator (PI) will promptly inform study participants and the Institutional Review Board 
(IRB), and will provide the reason(s) for the termination or suspension.  Study participants will be 
contacted, as applicable, and be informed of changes to study visit schedule.
 
Circumstances that may warrant termination or suspension include, but are not limited to:
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
30
Determination of unexpected, significant, or unacceptable risk to participants
Demonstration of efficacy that would warrant stopping   
Insufficient compliance to protocol requirements
Data that are not sufficiently complete and/or evaluable
Determination that the primary endpoint has been met
Determination of futility
Study may resume once concerns about safety, protocol compliance, and data quality are addressed, 
and satisfy the sponsor, IRB and/or Food and Drug Administration (FDA).
10.1.3 CONFIDENTIALITY AND PRIVACY 
Overview: The PI, Co-Investigators, and entire clinical research team adhere to stringent practices 
according to Yale HIC and HIPAA regulations to ensure participant confidentiality and privacy at all 
times. This confidentiality is extended to cover testing of participant samples, clinical data, genetic tests, 
and all other information generated or obtained during the study. All documents and participant 
information will be strictly maintained; only the PI, co-investigators and research team will have access 
to PHI, which will be limited to a “need to know” basis.  Data will be coded to maintain confidentiality. 
Only those investigators with appropriate Human Subjects training will have access to subject data.  All 
health care providers subject to HIPAA are required to protect the privacy of participant information.  
Research staffs at both the Yale School of Medicine and Yale-New Haven Hospital are required to 
comply with HIPAA and to ensure the confidentiality of patient/participant information.  All research 
activities will be conducted in as private a setting as possible; the CSRU and urology clinic space at both 
hospitals have individual patient rooms where subject visits will occur.   
Electronic records: All electronic files are encrypted, password protected, and stored on a secure server.  
Storing research data in OnCore®, Yale’s encrypted electronic clinical trials management system, will 
minimize the risk of a breach of confidentiality. 
Paper records: Minimal paper data will be kept in a locked file cabinet, in a locked office, in a locked 
suite at the Yale School of Medicine. Only the PI and immediate study staff will have access to the 
participant’s study records. Study forms will be coded with subject number to ensure that no personally 
identifiable information will be associated with these forms. The master list linking the code to 
participant/patient identifiers will be kept in a separate location than research data. Participant contact 
information will be securely stored for internal use during the study. At the end of the study, all paper 
records will continue to be kept in a secure location no longer than five years. 
Limited data sharing: Information about participants and their health which might identify them may be 
used by or given to the following individuals/entities, which are required to keep all information 
confidential: 
Yale Human Investigation Committee 
Medical personnel who provide services to participants in connection with this study (CSRU, YNHH,
      LMH, SCH)
Those providers who are participants in the Electronic Medical Record (EMR) system
Co-Investigators and other investigators (clinical trial consultant) 
Other members of the research team (laboratory investigators, statisticians)
Data and Safety Monitoring Committee and others authorized to monitor study conduct
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
31
Laboratory security measures: All blood samples provided in this study will be analyzed in a de-identified 
manner. Upon receipt, participant samples will be coded without PHI, before transfer to the Co-
Investigator lab-based team. The link between the participant’s code/ID # and PHI will be kept in the 
Clinical Trials Manager’s locked file cabinet.  Members of the laboratory-based study team will also 
examine biopsied prostate cancer tissue. No results of any genetic testing will appear in the participant’s 
medical record. The genetic testing is for research purposes only. The results will not be made available 
to the participant, their physician, or any treating physicians outside this study, or to any other clinical 
staff. These samples will be stored in Co-Investigator’s labs, which are locked when not in use. The 
samples will be used until they are exhausted. 
Record retention: Participant data will be kept for five years after the study ends. Data will be de-
identified using a “Safe Harbor” (45CFR164.514(b)(2)) approach consistent with the HIPAA Privacy rule.  
The principal investigator is responsible for the implementation of data de-identification.  The link to 
coded information will be destroyed and the data will become anonymous. The data will be kept in this 
anonymous form indefinitely.
Certificate of Confidentiality: A COC is not needed, and therefore has not been requested.  
10.1.4 FUTURE USE OF STORED SPECIMENS AND DATA 
Digital data collected for this study will be stored in OnCore and analyzed using an encrypted, password-
protected   server at the Yale School of Medicine.  After the study is completed, the de-identified, 
archived data will be stored as described in Section 10.1.3, Confidentiality and Privacy.  
The consent form for this study contains a section describing “Optional Specimens for Future 
Storage/Testing”, and allows the individual being consented the option to allow or not allow their 
samples and information to be stored and used for future research.  With the participant’s indication of 
approval on the form, the samples will be used to research the role of soy isoflavones on inhibiting 
disease progression or controlling prostate cancer cell growth. This may help researchers in the future 
learn more about signaling pathways in tumor cells, treatment of prostate cancer, inflammatory 
diseases and other health conditions.  Participants’ stored material will not be shared beyond the 
investigative team of this study.
During the conduct of the study, even after agreeing to allow banking of their specimens, a participant 
may choose to withdraw consent to have their biological specimens stored for future research.  
However, withdrawal of consent with regard to biosample storage may not be possible after the study is 
completed. 
10.1.5 KEY ROLES AND STUDY GOVERNANCE
Sponsor-Investigator
Michael S. Leapman, MD
Assistant Professor of Urology 
Yale University 
School of Medicine 
Urology
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
32
PO Box 208058
New Haven, CT  06520-8058 
203-785-3128
michael.leapman@yale.edu
As described below in sections 10.1.6 and 10.1.7, the Yale Center for Clinical Investigation (YCCI), the 
Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) will provide data and safety 
monitoring of this multi-site trial. 
 
Under the direction of the Sponsor-Investigator, the clinical trials manager will oversee daily operations 
of the study, with ongoing quality assurance and evaluation of all aspects of the clinical trial (e.g., 
recruitment, enrollment, randomization, study visits and data collection, IRB reporting, queries, and 
team communication), and will both apprise and consult the PI, co-investigators, and other team 
members as needed.  Aspects of (ancillary) laboratory tissue data analysis and blood chemistry data 
analysis are delegated to co-investigators and statisticians, under the direction of the Sponsor-
Investigator.
10.1.6 SAFETY OVERSIGHT
The Yale Cancer Center (YCC) Data and Safety Monitoring Committee (DSMC) will provide the primary 
oversight of data and safety monitoring. The Yale DSMC will review and monitor compliance, toxicity 
and deviations from this study. The committee is composed of clinical specialists with experience in 
oncology and who have no direct relationship with the study. Information that raises any questions 
about participant safety will be addressed with the Principal Investigator.
The DSMC will review this protocol bi-annually, at a minimum. Information to be provided to the 
committee includes: a study narrative by the PI, a summary DSMC report produced by OnCore® (which 
includes participant accrual, response, trial status history, SAEs, adverse events, deviations and survival); 
audit results, and monitoring reports, as applicable. Other information (e.g., scans, laboratory values, 
etc.) will be provided upon request. Upon completing the review, the DSMC will approve whether the 
study should continue as planned, require modification/ amendment, or be placed on administrative 
hold with accrual temporarily suspended.
Trials being monitored by the YCC DSMC will remain under the YCC DSMC purview until a DSMC review 
has occurred that includes the research activity of the last subject who completed the intervention, or 
until the DSMC feels there are no patient safety concerns that require further monitoring. The DSMC will 
determine the length of continued DSMC review.
The DSMC has authority to intervene in the conduct of these studies as necessary to ensure the safety of 
the participants and to maintain the highest quality in the clinical research performed at YCC. The DSMC 
has the authority to require additional monitoring and/ or more frequent reporting on study progress 
and serious adverse events. 
10.1.7 CLINICAL MONITORING
YCCI’s assigned Study Monitor (Clinical Research Associate) will monitor all essential documents and 
data for timeliness of submission, completeness, and adherence to protocol requirements. Monitoring 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
33
will begin at the time of participant registration and will continue during protocol performance until 
study completion. 
The principal investigator is responsible for monitoring the data, assuring protocol compliance, and 
conducting the safety reviews, formally at a quarterly basis. Safety data, however, is communicated to 
the investigators in real time. During the review process the principal investigator will evaluate whether 
the study should continue unchanged, require modification/amendment, or close to enrollment.
The principal investigator, the Yale University IRB, or the Yale Cancer Center Data and Safety Monitoring 
Committee have the authority to stop or suspend the study or require modifications.
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL
Under the direction of the Sponsor-Investigator the clinical trials manager will be responsible for 
addressing QA and QC issues and will oversee all activities related to study conduct according to the Yale 
IRB-approved application (HIC# 2000020868), and as stipulated in this protocol.  The Yale Center for 
Clinical Investigation monitors participant accrual and status on study through OnCore®.  All data 
changes to records are strictly audited. Examples of audit trail information available from the application 
include changes to subject demographics, changes to protocol status, and eCRF changes. 
The laboratory-based study team will perform pathological investigations and assays required for the 
secondary endpoint analyses according to GLPs.  All clinical and laboratory personnel on the study are 
current in GCP training.
10.1.9 DATA HANDLING AND RECORD KEEPING 
10.1.9.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES 
Ongoing processing and data collection is the responsibility of the clinical trials manager and research 
staff under the supervision of the principal investigator. The PI is responsible for ensuring the accuracy, 
completeness, legibility, and timeliness of the electronic medical record data reported (Epic Systems 
Corporation) regarding pre-biopsy serology and any recent imaging of the prostate.  The clinical trials 
manager is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the study 
visit data reported. 
All source documents will be completed in a neat, legible manner to ensure accurate interpretation of 
data.  The FACT-P questionnaire will be administered in paper form, for data entry into the OnCore® 
data management system. All paper forms will be coded with subject number; no personally identifiable 
information will be associated with these forms, kept in each study participant’s record and stored in a 
locked file cabinet.  All other clinical trial data (adherence, safety, anthropometrics, demographics) will 
be collected in real-time using OnCore®. The OnCore® system is encrypted, includes password 
protection and internal quality checks, such as automatic range checks to identify data that appear 
inconsistent, incomplete, or inaccurate.
Only the PI and study staff at the study’s data coordinating center (Yale School of Medicine/New Haven) 
site will have access to the participant’s study records. Additionally, all specimens collected will be 
coded with subject number so that no personally identifiable information will be associated with the 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
34
specimens.  Upon receipt of the samples for laboratory analysis of secondary endpoints telomere length, 
cell cycle progression of PCa mRNA, and markers of PCa tissue microarrays, the samples will be coded 
with the subject number (without PHI) before transfer to the laboratory on the Yale campus of co-
investigators responsible for these analyses. The link between the participant’s code/ID # and PHI will be 
kept in the clinical trial manager’s locked file cabinet.
In order for the PI and/or Clinical Trials Manager to receive surgical pathology reports of Dr. Renzulli’s 
patients at SCH  (biopsy report: to obtain CAPRA score variables – needed for randomization, 
and prostatectomy report:  to obtain CAPRA-S post-surgical score variables – a secondary outcome 
measure), Dr. Renzulli will utilize Yale’s Secure File Transfer.  Access to the Yale Secure File Transfer 
system (“Filelocker”) is gained though Yale’s Central Authentication Service.  Filelocker allows Yale NetId 
users to share files with other people both inside and outside of Yale University.  It is a temporary and 
secure storage system for sharing files and data.
10.1.9.2 STUDY RECORDS RETENTION 
All documents and subject information will be strictly maintained according to the Yale IRB and HIPAA 
regulations to ensure confidentiality at all times.  Access to subject information will be limited to a 
“need to know” basis and all data will be coded to maintain confidentiality. Only those investigators with 
appropriate Human Subjects training will have access to subject data. All data will be managed to assure 
strict confidentiality of participants at all times.  Data will be kept for five years after the study ends. 
Data will then be de-identified using a “Safe Harbor” (45CFR164.514(b)(2)) approach consistent with the 
HIPAA Privacy rule.  No records will be destroyed without the written consent of the principal 
investigator.
10.1.10
PROTOCOL DEVIATIONS 
A protocol deviation is any noncompliance with the Yale University IRB-approved clinical trial protocol. 
The noncompliance may be either on the part of the participant, the investigator, or study staff.  As a 
result of deviations, corrective and preventive actions will be developed by the principal investigator 
and relevant study team members and implemented promptly. 
It is the responsibility of the clinical trials manager to use continuous vigilance to identify and report 
deviations to the principal investigator as soon as the deviation becomes known.  Protocol deviations 
will be reported to the Yale IRB (per Yale’s HRPP Procedure 700 PR.1), if the deviation is determined 
major (using Yale’s HRPP Decision Tree 700 GD.1).  All investigators and study staff are responsible for 
knowing and adhering to protocol and IRB requirements. 
10.1.11
PUBLICATION AND DATA SHARING POLICY
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH-Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule. As 
such, this trial will be registered at ClinicalTrials.gov, and results information from this trial will be 
submitted to ClinicalTrials.gov. In addition, every attempt will be made to publish results in peer-
reviewed journals. 
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
35
In addition, this study will comply with the NIH Genomic Data Sharing Policy, which applies to all NIH-
funded research that generates large-scale human or non-human genomic data, as well as the use of 
these data for subsequent research. Large-scale data include genome-wide association studies (GWAS), 
single nucleotide polymorphisms (SNP) arrays, and genome sequence, transcriptomic, epigenomic, and 
gene expression data. 
10.1.12
CONFLICT OF INTEREST POLICY
The independence of this study from any actual or perceived influence, such as by an industry sponsor, 
is critical.  Therefore, any actual conflict of interest of persons who have a role in the design, conduct, 
analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons 
who have a perceived conflict of interest will be required to have such conflicts managed in a way that is 
appropriate to their participation in the design and conduct of this trial.  Yale University has established 
policies and procedures to disclose all conflicts of interest, and has a mechanism in place for the 
management of all reported dualities of interest by requiring conflict of interest disclosure reporting 
prior to protocol approval (and annually), for every individual listed on the protocol.
10.2 ADDITIONAL CONSIDERATIONS
In addition to the Yale University IRB, approval for the clinical trial protocol was received from the Yale 
Cancer Center Protocol Review Committee, on March 20, 2017.  
10.3 ABBREVIATIONS
AE
Adverse Event
ANCOVA
Analysis of Covariance
CAPRA
Cancer of the Prostate Risk Assessment
CAPRA-S
Cancer of the Prostate Risk Assessment Post-Surgical 
CFR
Code of Federal Regulations
CMC
Chemistry, Manufacturing and Controls
CMP
Clinical Monitoring Plan
COC
Certificate of Confidentiality
CONSORT
Consolidated Standards of Reporting Trials
CRF
Case Report Form
CTCAE
Common Terminology Criteria for Adverse Events
CTSA
Clinical and Translational Science Award
DHHS
Department of Health and Human Services
DSMC
Data Safety Monitoring Committee
eCRF
Electronic Case Report Form
FACT-P
Functional Assessment of Cancer Therapy – Prostate
FDA
Food and Drug Administration
FFR
Federal Financial Report
GCP
Good Clinical Practice
GLP
Good Laboratory Practices
GMP
Good Manufacturing Practices
GRAS
Generally Recognized as Safe 
GWAS
Genome-Wide Association Studies
HIC
Human Investigation Committee
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
36
HIPAA
Health Insurance Portability and Accountability Act 
HRPP
Human Research Protection Program
ICH
International Conference on Harmonisation 
IND
Investigational New Drug Application
IP
Investigational Product
IQR
Interquartile Range
IRB
Institutional Review Board
ISM
Independent Safety Monitor
ITT
Intention-To-Treat
LMH
Lawrence+Memorial Hospital
MedDRA
Medical Dictionary for Regulatory Activities 
NCT
National Clinical Trial
NIH 
National Institutes of Health
OHRP
Office for Human Research Protections
PCa
Prostate Cancer
PI
Principal Investigator
QA
Quality Assurance
QC
Quality Control
RCT
Randomized Controlled Trial
SAE
Serious Adverse Event
SAP
Statistical Analysis Plan
SCH
South County Hospital
SMC
Safety Monitoring Committee
SOA
Schedule of Activities
SOP
Standard Operating Procedure
UP
Unanticipated Problem
YNHH
Yale-New Haven Hospital
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019


APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019
Nutrition and Prostate Cancer
Version 3.1
Protocol 2000020868
01 November 2019
37
11
REFERENCES 
1.
Hackshaw-McGeagh LE, Perry RE, Leach VA, Qandil S, Jeffreys M, Martin RM, Lane JA. A 
systematic review of dietary, nutritional, and physical activity interventions for the prevention of prostate 
cancer progression and mortality. Cancer Causes Control. 2015;26(11):1521-50. doi: 10.1007/s10552-
015-0659-4. PubMed PMID: 26354897; PMCID: PMC4596907.
2.
Mahmoud AM, Yang W, Bosland MC. Soy isoflavones and prostate cancer: a review of 
molecular 
mechanisms. 
J 
Steroid 
Biochem 
Mol 
Biol. 
2014;140:116-32. 
doi: 
10.1016/j.jsbmb.2013.12.010. PubMed PMID: 24373791; PMCID: PMC3962012.
3.
Bektic J, Guggenberger R, Eder IE, Pelzer AE, Berger AP, Bartsch G, Klocker H. Molecular 
effects of the isoflavonoid genistein in prostate cancer. Clin Prostate Cancer. 2005;4(2):124-9. PubMed 
PMID: 16197614.
4.
Raynal NJ, Charbonneau M, Momparler LF, Momparler RL. Synergistic effect of 5-Aza-2'-
deoxycytidine and genistein in combination against leukemia. Oncol Res. 2008;17(5):223-30. PubMed 
PMID: 18980019.
5.
Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, 
Berg RE, Egge-Jacobsen W, Hammarstrom C, Svindland A, Kucuk O, Saatcioglu F, Tasken KA, Karlsen 
SJ. Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior 
to radical prostatectomy: a randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr 
Cancer. 2011;63(6):889-98. doi: 10.1080/01635581.2011.582221. PubMed PMID: 21714686.
6.
Yoo HW, Chang MJ, Kim SH. Fermented soybeans by Rhizopus oligosporus reduce femoral 
bone loss in ovariectomized rats. Nutrition research and practice. 2014;8(5):539-43. doi: 
10.4162/nrp.2014.8.5.539. PubMed PMID: 25324934; PMCID: 4198967.
7.
Yang Z, Liu S, Chen X, Chen H, Huang M, Zheng J. Induction of apoptotic cell death and in vivo 
growth inhibition of human cancer cells by a saturated branched-chain fatty acid, 13-methyltetradecanoic 
acid. Cancer research. 2000;60(3):505-9. PubMed PMID: 10676625.
8.
Lin T, Yin X, Cai Q, Fan X, Xu K, Huang L, Luo J, Zheng J, Huang J. 13-Methyltetradecanoic 
acid induces mitochondrial-mediated apoptosis in human bladder cancer cells. Urologic oncology. 
2012;30(3):339-45. doi: 10.1016/j.urolonc.2010.04.011. PubMed PMID: 20843711.
9.
Cai Q, Huang H, Qian D, Chen K, Luo J, Tian Y, Lin T, Lin T. 13-methyltetradecanoic acid 
exhibits anti-tumor activity on T-cell lymphomas in vitro and in vivo by down-regulating p-AKT and 
activating caspase-3. PLoS One. 2013;8(6):e65308. doi: 10.1371/journal.pone.0065308. PubMed PMID: 
23762338; PMCID: 3676434.
10.
Secor E, Weiss TR, Fields MF, Mehal WZ, Ali A. Characterization and Quality Control 
Assessment of a Novel Fermented Soy Beverage. J Altern Complement Med. 2016:P09.29. A139-40.
11.
Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for
improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117(22):5039-5046.
APPROVED BY THE YALE UNIVERSITY IRB 12/13/2019

SAP_001.pdf: 
1XWULWLRQDQG3URVWDWH&DQFHU
3URWRFRO1XPEHU
3ULQFLSDO,QYHVWLJDWRU0LFKDHO6
/HDSPDQ0' 
Amended Statistical Analysis Plan for the Terminated Study  
July 9, 2020 


1 
STATISTICAL CONSIDERATIONS  
Due to premature study termination (inability to enroll full sample size; indicated n and percent of 
target), the statistical analyses focused on the primary efficacy endpoint(s). Given the final sample 
size, it was deemed inappropriate to undertake full statistical analyses for the secondary outcomes. 
Instead, baseline, end of study and difference since baseline values were reported using the approach 
indicated in 1.1.1.  
 
1.1.1 GENERAL APPROACH    
 
Categorical data will be presented as counts and percentages. Continuous variables will be presented 
using mean with standard deviation and median with IQR. Graphical presentations will also be made as 
appropriate.  
 
Two-tailed, Type I error of 0.05 and 95% Confidence intervals will be used in analyses. 
 
The CAPRA score level (low/medium vs high) will be used to run a stratified primary outcome analysis. 
Other variables will be considered later in the SAP for use as covariates in subsequent analyses. 
Normality of distributions of continuous variables will be assessed and transformations (e.g. log, square 
root) will be considered, as appropriate, to normalize not normal distributions. In the event that normality 
cannot be achieved, nonparametric tests will be employed. 
 
1.1.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S) 
 
The primary outcome is change in serum PSA. This is the difference between the PSA value at baseline 
and the value at the time of admission for surgery (prostatectomy).  
 
‘Baseline’ is defined as the date that an eligible participant enrolls in the trial; randomization will occur 
within 3 days of baseline assessment. If no measurement is available in this 3-day window, the first 
measurement after randomization BUT before the date of treatment initiation and up to day 7, will be 
defined as baseline.  
 
Repeated measures analysis or linear mixed models analysis will be used to assess whether the mean 
change in PSA from pre to post-treatment differs in the two groups.  This can be achieved by measuring 
the (time by group) interaction term in a repeated measures ANOVA. 
 
In secondary analysis of the primary outcome, the difference in PSA mean level at post-intervention/pre-
surgery between the two groups will be assessed using ANCOVA and adjusting for pre-
intervention/baseline values. This analytical approach will test whether the QC group has a higher PSA 
mean level following treatment. Adjusting for pre-treatment/baseline PSA level ensures that any post-
treatment differences are a consequence of treatment, and not a result of some random effect from the 
pre-treatment differences between the groups. In addition, variation in the post-treatment means 
stemming from the variation introduced from the pre-treatment participant starting point. 
 
Stratified analysis (low/medium vs. high CAPRA score) will also be carried out. 
 
 
 


 
1.1.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)   
 
A number of secondary outcomes will be summarized and compared between the two trial arms. 
 
A. Assessed pre and post-surgery 
 
Continuous variables: 
1. Prostate cancer tissue telomeric DNA length  
 
2. Cell cycle progression score assessment of prostate cancer mRNA from prostate cancer tissue  
 
Ordinal variables: 
 
1. Gleason score compared to preoperative biopsies  
 
2. Quality of life (FACT-P)